Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Inflammopharmacology
Erschienen in:

10.01.2022 | Original Article

Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model

verfasst von: Pariya Khodabakhsh, Nilgoon Khoie, Ahmad-Reza Dehpour, Alireza Abdollahi, Mahmoud Ghazi-Khansari, Hamed Shafaroodi

Erschienen in: Inflammopharmacology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Irritable bowel syndrome (IBS) is a functional gut disorder with multi-factorial pathophysiology that causes recurring pain or discomfort in the abdomen, as well as altered bowel habits. Montelukast, a well-known cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, is widely used for the anti-inflammatory management of asthma. The present study aimed to evaluate the effects of pharmacological inhibition of CysLT1R on acetic acid-induced diarrhea-predominant IBS (D-IBS) in rats. Behavioral pain responses to noxious mechanical stimulation were decreased in the montelukast-treated rats as compared to the model animals following colorectal distension (CRD)-induced visceral hypersensitivity. Stool frequency decreased dose-dependently by montelukast in IBS rats exposed to restraint stress. A significantly shorter immobility time was also observed in IBS rats who received montelukast vs IBS group in the forced swimming test (depression-like behavior). Furthermore, there were significant decreases in the NF-κB protein expression, inflammatory cytokine (TNF-α, and IL-1ß) levels, and histopathological inflammatory injuries concomitant with increased anti-inflammatory cytokine, IL-10, in montelukast-treated rats compared with the IBS group. Cysteinyl leukotriene production and CysLT1R mRNA expression showed no remarkable differences among the experimental groups. The present results suggest the possible beneficial effects of montelukast in the management of D-IBS symptoms. The molecular mechanism underlying such effects, at least to some extent, might be through modulating CysLT1R-mediated NF-κB signaling. Yet, more studies are required to demonstrate the clinical potential of this drug for IBS therapy.
Literatur
Abdullayev R, Makhmudova L (2021) Features of chemical elements in various forms of irritable bowel syndrome. Ann Rom Soc Cell Biol 25:2993–3000
Al-Chaer ED, Kawasaki M, Pasricha PJ (2000) A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 119:1276–1285PubMed
Bäck M, Powell WS, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE (2014) Update on leukotriene, lipoxin and oxoeicosanoid receptors: iuphar review 7. Br J Pharmacol 171:3551–3574PubMedPubMedCentral
Camilleri M (2012) Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 367:1626–1635PubMed
Cangemi DJ, Lacy BE (2019) Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. Ther Adv Gastroenterol 12:1756284819878950
Capra V, Bäck M, Barbieri SS, Camera M, Tremoli E, Rovati GE (2013) Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev 33:364–438PubMed
Chowdhury M, Uddin M, Das S, Hoque M (2013) Montelukast in allergic rhinitis: a review. Med Today 24:75–78
Çikler E, Ersoy Y, Çetinel Ş, Ercan F (2009) The leukotriene D4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress. Acta Histochem 111:112–118PubMed
Cojocariu RO, Balmus IM, Lefter R, Ababei DC, Ciobica A, Hritcu L, Kamal F, Doroftei B (2020) Behavioral and oxidative stress changes in mice subjected to combinations of multiple stressors relevant to irritable bowel syndrome. Brain Sci 10:865PubMedCentral
Colomier E, Algera J, Melchior C (2021) Pharmacological therapies and their clinical targets in irritable bowel syndrome with diarrhea. Front Pharmacol 11:2464
Dong Y, Baumeister D, Berens S, Eich W, Tesarz J (2019) High rates of non-response across treatment attempts in chronic irritable bowel syndrome: results from a follow-up study in tertiary care. Front Psych 10:714
Fee WH (2002) Irritable bowel syndrome helped by montelukast. Chest J 122:1497–1497
Ghorbanzadeh B, Mansouri MT, Sahraei H, Alboghobeish S (2016) Involvement of opioid receptors in the systemic and peripheral antinociceptive actions of montelukast in the animal models of pain. Eur J Pharmacol 779:38–45PubMed
He X, Cui L-H, Wang X-H, Yan Z-H, Li C, Gong S-D, Zheng Y, Luo Z, Wang Y (2017) Modulation of inflammation by toll-like receptor 4/nuclear factor-kappa b in diarrhea-predominant irritable bowel syndrome. Oncotarget 8:113957PubMedPubMedCentral
Herbst-Robinson KJ, Liu L, James M, Yao Y, Xie SX, Brunden KR (2015) Inflammatory eicosanoids increase amyloid precursor protein expression via activation of multiple neuronal receptors. Sci Rep 5:1–16
Holma R, Salmenperä P, Riutta A, Virtanen I, Korpela R, Vapaatalo H (2001) Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats. Eur J Pharmacol 429:309–318PubMed
Holma R, Salmenperä P, Virtanen I, Vapaatalo H, Korpela R (2007) Prophylactic potential of montelukast against mild colitis induced by dextran sulphate sodium in rats. J Physiol Pharmacol 58:455–467PubMed
Hosseindoost S, Hashemizadeh S, Gharaylou Z, Dehpour AR, Javadi SAH, Arjmand B, Hadjighassem M (2020) Β2-adrenergic receptor stimulation upregulates cx43 expression on glioblastoma multiforme and olfactory ensheathing cells. J Mol Neurosci 70:1451–1460PubMed
Huang X-Q, Zhang X-Y, Wang X-R, Yu S-Y, Fang S-H, Lu Y-B, Zhang W-P, Wei E-Q (2012) Transforming growth factor Β1-induced astrocyte migration is mediated in part by activating 5-lipoxygenase and cysteinyl leukotriene receptor 1. J Neuroinflammation 9:145PubMedPubMedCentral
Ince I, Yoruk O, Ahiskalioglu A, Aksoy M, Dostbil A, Celik M (2015) Does montelukast have an effect on post-tonsillectomy pain control in children? A randomized trial study. Otolaryngol Head Neck Surg 153(2):269–274PubMed
Kabasakal L, Şener G, Çetinel Ş, Contuk G, Gedik N, Yeğen BÇ (2005) Burn-induced oxidative injury of the gut is ameliorated by the leukotriene receptor blocker montelukast. Prostaglandins Leukot Essent Fat Acids 72:431–440
Khodabakhsh P, Bazrgar M, Dargahi L, Mohagheghi F, Taei AA, Parvardeh S, Ahmadiani A (2021) Does Alzheimer’s disease stem in the gastrointestinal system? Life Sci 287:120088PubMed
La J-H, Kim T-W, Sung T-S, Kang J-W, Kim H-J, Yang I-S (2003) Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis. World J Gastroenterol 9:2791–2795PubMedPubMedCentral
Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ (2007) Immune activation in patients with irritable bowel syndrome. Gastroenterology 132:913–920PubMed
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative pcr and the 2 Δδc T method. Methods 25:402–408
Maeba S, Ichiyama T, Ueno Y, Makata H, Matsubara T, Furukawa S (2005) Effect of montelukast on nuclear factor κb activation and proinflammatory molecules. Ann Allergy Asthma Immunol 94:670–674PubMed
Magnusson C, Mezhybovska M, Lörinc E, Fernebro E, Nilbert M, Sjölander A (2010) Low expression of cyslt 1 R and high expression of cyslt 2 R mediate good prognosis in colorectal cancer. Eur J Cancer 46:826–835PubMed
Mahgoub AA, El-Medany AA, Hager HH, Mustafa AA, El-Sabah DM (2003) Evaluating the prophylactic potential of zafirlukast against the toxic effects of acetic acid on the rat colon. Toxicol Lett 145:79–87PubMed
Manabe N, Tanaka T, Hata J, Kusunoki H, Haruma K (2009) Pathophysiology underlying irritable bowel syndrome-from the viewpoint of dysfunction of autonomic nervous system activity. J Smooth Muscle Res 45:15–23PubMed
Metters KM (1995) Leukotriene receptors. J Lipid Mediat Cell Signal 12:413–427PubMed
Mohamadin AM, Elberry AA, Elkablawy MA, Gawad HSA, Al-Abbasi FA (2011) Montelukast, a leukotriene receptor antagonist abrogates lipopolysaccharide-induced toxicity and oxidative stress in rat liver. Pathophysiology 18:235–242PubMed
Nayak A, Langdon RB (2007) Montelukast in the treatment of allergic rhinitis. Drugs 67:887–901PubMed
Nishikawa M, Hikasa Y, Hori K, Tanida N, Shimoyama T (1995) Effect of leukotriene C 4 D 4 antagonist on colonic damage induced by intracolonic administration of trinitrobenzene sulfonic acid in rats. J Gastroenterol 30:34–40PubMed
Paragomi P, Rahimian R, Kazemi MH, Gharedaghi MH, Khalifeh-Soltani A, Azary S, Javidan AN, Moradi K, Sakuma S, Dehpour AR (2014) Antinociceptive and antidiarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: role of nitric oxide. Clin Exp Pharmacol Physiol 41:118–126PubMed
Pons L, Droy-Lefaix M-T, Bueno L (1992) Leukotriene D 4 participates in colonic transit disturbances induced by intracolonic administration of trinitrobenzene sulfonic acid in rats. Gastroenterology 102:149–156PubMed
Porsolt R, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336PubMed
Pournajaf S, Valian N, Shalmani LM, Khodabakhsh P, Jorjani M, Dargahi L (2020) Fingolimod increases oligodendrocytes markers expression in epidermal neural crest stem cells. Eur J Pharmacol 885:173502PubMed
Qin H-Y, Xiao H-T, Wu JC, Berman BM, Sung JJ, Bian Z-X (2012) Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats. World J Gastroenterol WJG 18:2481PubMed
Riccioni G, Di Ilio C, Conti P, Theoharides TC, D’orazio N (2004) Advances in therapy with antileukotriene drugs. Ann Clin Lab Sci 34:379–387PubMed
Schoors D, Smet M, Reiss T, Margolskee D, Cheng H, Larson P, Amin R, Somers G (1995) Single dose pharmacokinetics, safety and tolerability of Mk-0476, a new leukotriene d4-receptor antagonist, in healthy volunteers. Br J Clin Pharmacol 40:277–280PubMedPubMedCentral
Shamshiri H, Paragomi P, Paydar MJ, Moezi L, Bahadori M, Behfar B, Ardalan FA, Dehpour AR (2009) Antinociceptive effect of chronic lithium on visceral hypersensitivity in a rat model of diarrhea-predominant irritable bowel syndrome: the role of nitric oxide pathway. J Gastroenterol Hepatol 24:672–680PubMed
Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N (2007) Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56:1770–1798PubMedPubMedCentral
Sung TS, La J-H, Kang TM, Kim TW, Yang I-S (2015) Visceral hypersensitivity and altered colonic motility in type 2 diabetic rat. J Neurogastroenterol Motil 21:581PubMedPubMedCentral
Taei AA, Nasoohi S, Hassanzadeh G, Kadivar M, Dargahi L, Farahmandfar M (2021) Enhancement of angiogenesis and neurogenesis by intracerebroventricular injection of secretome from human embryonic stem cell-derived mesenchymal stem cells in ischemic stroke model. Biomed Pharmacother 140:111709
Tel BC, Telli G, Onder S, Nemutlu E, Bozkurt TE (2021) Investigation of the relationship between chronic montelukast treatment, asthma and depression-like behavior in mice. Exp Ther Med 21:1–1
Wang L, Du C, Lv J, Wei W, Cui Y, Xie X (2011) Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 187:2336–2345PubMed
Wang H, Shi Q, Shi W, Zhang X, Wang X, Zhang L, Fang S, Lu Y, Zhang W, Wei E (2013) Expression and distribution of cysteinyl leukotriene receptors cyslt1r and cyslt2r, and gpr17 in brain of parkinson disease model mice. Zhejiang da xue xue bao. Yi xue ban= journal of zhejiang university. Med Sci 42:52–60
Wu S, Zhu X, Jin Z, Tong X, Zhu L, Hong X, Zhu X, Liu P, Shen W (2015) The protective role of montelukast against intestinal ischemia-reperfusion injury in rats. Sci Rep 5(1):1–9
Yu G-L, Wei E-Q, Zhang S-H, Xu H-M, Chu L-S, Zhang W-P, Zhang Q, Chen Z, Mei R-H, Zhao M-H (2004) Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose-and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 73:31–40PubMed
Yu G-L, Wei E-Q, Wang M-L, Zhang W-P, Zhang S-H, Weng J-Q, Chu L-S, Fang S-H, Zhou Y, Chen Z (2005) Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Brain Res 1053:116–125PubMed
Yu S-Y, Zhang X-Y, Wang X-R, Xu D-M, Chen L, Zhang L-H, Fang S-H, Lu Y-B, Zhang W-P, Wei E-Q (2014) Cysteinyl leukotriene receptor 1 mediates ltd4-induced activation of mouse microglial cells in vitro. Acta Pharmacol Sin 35:33–40PubMed
Yu X-B, Dong R-R, Wang H, Lin J-R, An Y-Q, Du Y, Tang S-S, Hu M, Long Y, Sun H-B (2016) Knockdown of hippocampal cysteinyl leukotriene receptor 1 prevents depressive behavior and neuroinflammation induced by chronic mild stress in mice. Psychopharmacology 233:1739–1749PubMed
Zhang Y-J, Zhang L, Wang S-B, Shen H-H, Wei E-Q (2004) Montelukast modulates lung cyslt (1) receptor expression and eosinophilic inflammation in asthmatic mice. Acta Pharmacol Sin 25:1341–1346PubMed
Zhou C, Shi X, Huang H, Zhu Y, Wu Y (2014) Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa b in a rat model of chronic constriction injury. Anesth Analg 118:1090–1096PubMed
Metadaten
Titel
Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model
verfasst von
Pariya Khodabakhsh
Nilgoon Khoie
Ahmad-Reza Dehpour
Alireza Abdollahi
Mahmoud Ghazi-Khansari
Hamed Shafaroodi
Publikationsdatum
10.01.2022
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 1/2022
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-021-00907-7

Weitere Artikel der Ausgabe 1/2022

Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection

The analgesic effect and safety of preoperative versus postoperative administration of celecoxib in patients who underwent arthroscopic rotator cuff repair: a randomized, controlled study

  • Original Article

Correction to: The effect of glutamine supplementation on serum levels of some inflammatory factors, oxidative stress, and appetite in COVID-19 patients: a case–control study

In vitro and in vivo anti-inflammatory activity of Tetrastigma sulcatum leaf extract, pure compound and its derivatives

  • Original Article

The effects of phytochemicals and herbal bio-active compounds on tumour necrosis factor-α in overweight and obese individuals: a clinical review

  • Review

Anti-inflammatory and anti-COVID-19 effect of a novel polyherbal formulation (Imusil) via modulating oxidative stress, inflammatory mediators and cytokine storm

  • Zur Zeit gratis
  • COVID-19
  • Original Article